How long does Rhamnus frangula take to work?

Rhamnus frangula bark typically produces a bowel movement within 6 to 12 hours of ingestion, which is why it is commonly taken at bedtime for morning relief. This onset is slower than osmotic laxatives but results from bacterial conversion of glucofrangulins into active aglycones in the colon.

What is the recommended dosage of Rhamnus frangula for constipation?

The EMA-recommended dose for adults is the minimum amount providing 20–30 mg of hydroxyanthracene derivatives per day, calculated as frangulin A. This typically corresponds to 0.5–2.5 g of dried bark in tea or standardized extract form, taken once daily in the evening and not exceeding 1–2 weeks of consecutive use.

Is Rhamnus frangula safe to use long-term?

Long-term use of Rhamnus frangula is not considered safe and is explicitly discouraged by EMA and WHO guidelines. Chronic use beyond 1–2 weeks risks hypokalemia, laxative dependence, and pseudomelanosis coli—a reversible but clinically significant discoloration of the colon mucosa caused by accumulated anthraquinone metabolites.

Does Rhamnus frangula interact with any medications?

Yes, the most clinically significant interaction is with cardiac glycosides such as digoxin, where hypokalemia induced by anthraquinone laxatives increases the risk of toxicity. Concurrent use with other potassium-depleting drugs, including corticosteroids and thiazide diuretics, compounds this risk, and patients on antiarrhythmic medications should avoid Rhamnus frangula without medical supervision.

What is the difference between Rhamnus frangula and Rhamnus purshiana (cascara)?

Both Rhamnus frangula and Rhamnus purshiana (cascara sagrada) are anthraquinone-containing laxatives, but they differ in their specific glycoside profiles: frangula bark contains glucofrangulins and frangulins, while cascara contains cascarosides A–D. Frangula is generally regarded as producing a milder, more predictable laxative effect and is more widely recognized in European pharmacopeias, whereas cascara was historically used in North American traditional medicine and was classified as an OTC laxative by the FDA before its 2002 withdrawal due to insufficient safety data.

Is Rhamnus frangula safe during pregnancy and breastfeeding?

Rhamnus frangula is contraindicated during pregnancy and breastfeeding due to its stimulant laxative properties, which may increase uterine contractions and risk of miscarriage, and can pass into breast milk affecting infants. WHO and EMA monographs recommend avoiding use in these populations. Pregnant or nursing women should consult a healthcare provider before considering this ingredient.

Who should avoid Rhamnus frangula and why?

Individuals with inflammatory bowel disease, intestinal obstruction, abdominal pain of unknown origin, appendicitis, or severe dehydration should avoid Rhamnus frangula. Additionally, children under 12 years and those with chronic constipation requiring ongoing management are not suitable candidates, as this ingredient is intended only for short-term, occasional constipation relief.

What does clinical research show about the effectiveness of Rhamnus frangula?

Clinical evidence supports Rhamnus frangula's efficacy in stimulating colonic peristalsis and accelerating intestinal transit through its anthraquinone glycoside content, with results typically observed within 8–12 hours. The WHO and EMA recognize its traditional use as a well-established remedy for short-term constipation relief. However, evidence for its preliminary antifungal and virucidal properties remains limited to in-vitro studies and lacks robust clinical confirmation in humans.

Rhamnus frangula

Rhamnus frangula (alder buckthorn) is a medicinal shrub whose bark contains anthraquinone glycosides, primarily glucofrangulin A and B, which stimulate colonic peristalsis and accelerate intestinal transit. These compounds act on the large intestine's myenteric plexus and inhibit water reabsorption, producing a laxative effect within 6–12 hours.

Category: Other Evidence: 2/10 Tier: Traditional

Rhamnus frangula — Hermetica Encyclopedia

Origin & History

Rhamnus frangula L. (frangula bark) is the dried bark from a shrub native to Europe, western Asia, and northern Africa, harvested from 2- to 6-year-old branches and stored for at least one year to develop active anthraquinone content. The bark is standardized to contain 6.5-15% hydroxyanthracene derivatives (HAD) in herbal preparations.

Historical & Cultural Context

Used in European traditional medicine for occasional constipation as a stimulant laxative, with documented use in pharmacopoeial monographs including WHO 2002, ESCOP, and Ph. Eur. Historical use is recognized under Article 10a of Directive 2001/83/EC for well-established medicinal products.

Health Benefits

• Short-term relief of occasional constipation - well-established traditional use recognized by EMA/WHO monographs
• Stimulation of colonic peristalsis and accelerated intestinal transit - mechanism demonstrated through anthraquinone glycoside activity
• Potential antifungal activity against Aspergillus fumigatus - preliminary in-vitro evidence only
• Virucidal effects against herpes simplex type 1 (ID50 0.35 μg/mL) - preliminary in-vitro evidence only
• Inhibition of platelet aggregation through frangulin B - preliminary mechanistic evidence only

How It Works

The active anthraquinone glycosides in Rhamnus frangula bark—glucofrangulin A, glucofrangulin B, frangulin A, and frangulin B—are hydrolyzed by colonic bacteria into aglycone frangulaemodin, which stimulates the myenteric plexus nerve endings to increase colonic smooth muscle contractions. Simultaneously, these metabolites inhibit Na+/K+-ATPase in enterocytes, reducing electrolyte and water reabsorption in the colon, thereby softening stool and increasing luminal pressure. The net effect is accelerated large intestinal transit, typically producing a bowel movement within 6–12 hours of ingestion.

Scientific Research

No human clinical trials, RCTs, or meta-analyses are detailed in the available research. Evidence relies entirely on well-established traditional use and pharmacovigilance data rather than modern clinical studies, with German authorities restricting use in 1996 due to safety concerns.

Clinical Summary

Evidence supporting Rhamnus frangula is largely derived from traditional use data, pharmacological mechanistic studies, and a limited number of small clinical trials rather than large randomized controlled trials. The EMA and WHO have granted 'well-established use' status for short-term constipation relief based on accumulated historical and observational data spanning decades. One comparative study found bark preparations producing bowel movements in 6–12 hours at standardized doses of 20–30 mg hydroxyanthracene derivatives daily, comparable to senna in efficacy. Overall evidence is considered moderate for short-term symptomatic use, with long-term efficacy and safety data remaining insufficient.

Nutritional Profile

Rhamnus frangula (Alder Buckthorn) bark is not consumed as a food ingredient and therefore lacks a conventional macronutrient/micronutrient profile. Its pharmacological relevance is defined by its bioactive phytochemical constituents rather than nutritional value. Key bioactive compounds include: Anthraquinone glycosides (total content 3–7% dry weight of aged/dried bark per European Pharmacopoeia standards), primarily glucofrangulin A and glucofrangulin B (together comprising ~60–70% of total anthraquinone fraction), frangulin A (frangula-emodin-6-O-rhamnoside) and frangulin B (frangula-emodin-6-O-glucoside), and free aglycones including frangula-emodin and chrysophanol at lower concentrations (<0.5% dry weight). Fresh bark additionally contains anthrone and anthranol precursors which are toxic and require minimum 1-year aging or heat treatment to oxidize to pharmacologically active anthraquinone forms. Minor constituents include tannins (approximately 2–3%), flavonoids including quercetin and kaempferol glycosides (trace amounts, <0.5%), triterpenes including oleanolic and ursolic acids (~0.1–0.3%), and small quantities of volatile compounds including methyl-2-furoate. Bioavailability note: anthraquinone glycosides are largely unabsorbed in the small intestine, reaching the colon intact where bacterial hydrolysis releases active aglycones; systemic absorption is minimal, which is pharmacologically desirable for laxative effect but limits any systemic bioavailability. Macronutrient content (protein, fat, digestible carbohydrates) is negligible and nutritionally irrelevant given medicinal-only dosing context (typical bark powder dose: 0.5–2.5g/day).

Preparation & Dosage

Dry extract standardized to 6.5-15% HAD: 10-30 mg HAD per day, taken once at bedtime for maximum 1-2 weeks. Herbal tea preparations from cut bark are available but without specific dosage quantification. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Psyllium husk, probiotics, magnesium citrate, senna, cascara sagrada

Safety & Interactions

Rhamnus frangula should not be used for more than 1–2 consecutive weeks, as chronic use can cause electrolyte imbalances, particularly hypokalemia, which may potentiate cardiac glycosides such as digoxin and interact with antiarrhythmic drugs. It is contraindicated in intestinal obstruction, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), appendicitis, abdominal pain of unknown origin, and in children under 12 years. Use during pregnancy and breastfeeding is contraindicated due to the potential stimulant effect on uterine smooth muscle and possible excretion of anthraquinone metabolites into breast milk. Long-term misuse may lead to pseudomelanosis coli, a reversible pigmentation of the colon lining that resolves after discontinuation.